Detalles de la búsqueda
1.
Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.
Wien Klin Wochenschr
; 135(13-14): 364-374, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286910
2.
Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries.
Europace
; 13(1): 23-30, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20823043
3.
Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
J Blood Med
; 12: 115-122, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33664606
4.
Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Expert Rev Pharmacoecon Outcomes Res
; 21(1): 29-42, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33307885
5.
Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Eur Neuropsychopharmacol
; 27(8): 773-781, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28663124
6.
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Expert Rev Pharmacoecon Outcomes Res
; 17(3): 293-302, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27680105
7.
Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
Curr Med Res Opin
; 32(2): 351-66, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26637048
Resultados
1 -
7
de 7
1
Próxima >
>>